Trial Profile
Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 07 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 05 Apr 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.